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Background and Objectives: Atrial fibrillation is a common abnormal cardiac rhythm
caused by disorganized electrical impulses. AF which is refractory to antiarrhythmic
management is often treated with catheter ablation. Recently a novel ablation system
(nMARQ) was introduced for PV isolation. However, there has not been a systematic
review of its efficacy or safety compared to traditional ablation techniques. Therefore, we
conducted this meta-analysis on the nMARQ ablation system.
Methods: PubMed and EMBASE were searched up until 1st of September 2017 for
articles on nMARQ. A total of 136 studies were found, and after screening, 12 studies
were included in this meta-analysis.
Results: Our meta-analysis shows that the use of nMARQ was associated with higher
odds of AF non-recurrence (n = 1123, odds ratio =6.79, 95% confidence interval
4.01–11.50; P < 0.05; I2 took a value of 83%). Moreover, the recurrence rate of AF using
nMARQ was not significantly different from that of traditional ablation procedures (n =
158 vs. 196; OR = 0.97, 95% confidence interval:0.59–1.61). No significant difference in
complication rates was observed between these groups (RR: 0.86; 95% CI: 0.37–1.99;
P > 0.05). There were four reported mortalities in the nMARQ group compared to none
in the conventional ablation group (relative risk: 1.58; 95% CI: 0.09–29.24; P > 0.05).
Li et al. nMARQ for Atrial Fibrillation
Conclusions: AF recurrence rates are comparable between nMARQ and conventional
ablation techniques. Although general complication rates are similar for both groups, the
higher mortality with nMARQ suggests that conventional techniques should be used for
resistant AF until improved safety profiles of nMARQ can be demonstrated.
Keywords: nMARQ, nMARQTM, ablation, atrial fibrillation, recurrence
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia
encountered in clinical practice. It can have both re-entrant and
triggered mechanisms (Tse et al., 2016), the latter exemplified
by impulses originating from the roots of the pulmonary veins
(Hu et al., 2015). One of the major concerns associated with
AF is an increased risk of thrombo-embolic events (stroke
or systemic embolism). Anticoagulation therapies are therefore
recommended in all patients with AF who are at moderate-
to-high risk of stroke (Singer et al., 2008; Camm et al., 2010),
which include the presence of co-morbidities such as type
2 diabetes mellitus (Marfella et al., 2013; Steinberg et al.,
2015). As well as the increased risk of thrombo-embolic events,
AF also remains a major aetiological factor of heart failure
and increased hospitalization rates. As such, establishing an
effective monitoring system for early AF detection along with
an effective approach to treating AF is essential (Sardu et al.,
2016).
Numerous studies have demonstrated the superiority
of interventions over pharmacological approaches for the
maintenance of sinus rhythm in patients with both paroxysmal
and persistent AF. Considering that the pulmonary vein (PV)
can produce rapid focal activation that contributes to AF
persistence, disruption of the electrical connection between
the left atrium and the left and right PVs by circumferential
PV isolation may prevent occurrence of the arrhythmia
(Calkins et al., 2012b; Camm et al., 2012). Apart from
the irrigated single-tip, point-by-point delivery technique,
innovative technologies such as single-shot devices, balloon
technology, and circumferential multipolar ablation catheters
have been introduced over the last decade as alternatives for
ablation procedures. These new ablation tools have allowed
for safer and more efficient isolation by applying different
forms of energy to create linear lesions at the peri-PV ostia
region (Deneke et al., 2011; Schade et al., 2012; Packer et al.,
2013).
Recently, circular irrigated radiofrequency ablation using the
novel ablation system, nMARQ, (Biosense Webster, Diamond
Bar, CA, USA) has been introduced for circumferential
PV isolation. Several studies have compared nMARQ with
conventional ablation tools. However, the definite efficacy of this
new system has not been clearly elucidated due to differing results
from the studies and there has not been a systematic evaluation
to date. In this study, we therefore conducted a systematic review
and meta-analysis to examine AF recurrence as well as peri-
procedural complications between the nMARQ ablation system
and traditional ablation techniques.
Pathophysiology of AF
Currently, a combination of triggered and re-entrant
mechanisms involving not only the atrium itself but structures
such as ganglionated plexi and the pulmonary veins have been
proposed to underlie the generation and maintenance of AF
(Calkins et al., 2012a). Autonomic modulation is thought to
be an important mediator of arrhythmogenesis (Marrouche
et al., 2014; Rizzo et al., 2015). Recently, Yang Felix et al.
proposed a common pathophysiological pathway that can
cause the development and progression of AF associated with
inflammatory and fibrotic changes (Yang et al., 2017). This
was supported by Cochet et al. who described the difference in
atrial fibrosis distribution between patients with and without AF
(Cochet et al., 2015).
METHODS
Search Strategy, Inclusion, and Exclusion
Criteria
The meta-analysis was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
statement (Moher et al., 2009). PubMed and EMBASE were
searched for studies that investigated AF recurrence rates using
nMARQ and/or conventional ablation techniques. The following
terms were used: “nMARQ” and “nMARQTM.” The search
period was from the beginning of the databases through to 1st
September 2017 with no language restrictions. The following
inclusion criteria were applied: (i) the design was a case-control,
prospective or retrospective cohort study in humans, (ii) AF
recurrence and complication rates were reported for nMARQ
with or without comparison to conventional ablation techniques.
Included studies also adhered to the follow-up recommendations
post-ablation from the 2016 ESC guidelines for the management
of atrial fibrillation developed in collaboration with EACTS.
These suggest that “patients should be seen at least once by a
rhythm specialist in the first 12 months after ablation” (Kirchhof
et al., 2016).
The quality assessment of these studies included in our meta-
analysis was performed using the Newcastle–Ottawa Quality
Assessment Scale (NOS). The point score system evaluated the
categories of study participant selection, comparability of the
results, and quality of the outcomes. The following characteristics
were assessed: (a) representativeness of the exposed cohort;
(b) selection of the non-exposed cohort; (c) ascertainment of
exposure; (d) demonstration that outcome of interest was not
present at the start of study; (e) comparability of cohorts on the
basis of the design or analysis; (f) assessment of outcomes; (g)
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follow-up period sufficiently long for outcomes to occur; and (h)
adequacy of follow-up of cohorts. This scale varied from zero
to nine stars, which indicated that studies were graded as poor
quality if they met <5 criteria, fair if they met 5 to 7 criteria,
and good if they met >8 criteria. The details of the NOS quality
assessment are shown in Supplementary Table 1.
Data Extraction and Statistical Analysis
Data from the studies were entered in a pre-specified spreadsheet
in Microsoft Excel. All publications identified were assessed for
compliance with the inclusion criteria. In this meta-analysis
the extracted data elements consisted of: (i) publication details:
surname name of first author, publication year; (ii) study design;
(iii) follow-up duration; (iv) the quality score; and (v) the
characteristics of the population including sample size, gender,
age. Two reviewers (CL and MD) independently reviewed each
included study and disagreements were resolved by adjudication
with input from a third reviewer (TL). Research findings from
abstracts are frequently significantly different from the final
publication and have not undergone the same degree of rigorous
peer review process as normally required for journal articles. For
these reasons only full-text publications were included in this
meta-analysis.
Heterogeneity across studies was determined using Cochran’s
Q-value and the I2 statistic from the standard chi-square test.
Cochran’s Q-value is the weighted sum of squared differences
between individual study effects and the pooled effect across
studies. The I2 statistic from the standard chi-square test
describes the percentage of variability in the effect estimates
resulting from heterogeneity. I2 > 50% was considered to reflect
significant statistical heterogeneity. The random-effects model
using the inverse variance heterogeneity method was used with
I2 > 50%. To locate the origin of the heterogeneity, subgroup
analyses based on different disease conditions and different
endpoints were performed. Sensitivity analysis excluding one
study at a time was also performed. Funnel plots showing
standard errors or precision against the logarithms of the odds
ratio were constructed. The Begg andMazumdar rank correlation
test and Egger’s test were used to assess for possible publication
bias.
RESULTS
Efficacy of the nMARQ Ablation Technique
A flow diagram detailing the above search strategy with inclusion
and exclusion criteria is shown in Figure 1. A total of 31
publications were found and further assessment demonstrated
that 13 met the inclusion criteria. The Kiss et al. (2014) study
was excluded due to AF recurrence not being reported as an
endpoint. Therefore, a total of 12 studies were included in this
meta-analysis (Scaglione et al., 2014; Zellerhoff et al., 2014; Dello
Russo et al., 2015; Farkash et al., 2015; Mahida et al., 2015;
Burri et al., 2016; Laish-Farkash et al., 2016; Lauschke et al.,
2016; Rodriguez-Entem et al., 2016; Rosso et al., 2016; Vurma
et al., 2016; Wakili et al., 2016). Of these, six reported efficacy
of the novel nMARQ ablation system without any comparison.
Four studies compared it to other ablation techniques such as
FIGURE 1 | Flowchart of the database search and study selection process.
single-catheter ablation catheterisation (SAC) (Lauschke et al.,
2016; Wakili et al., 2016), “Smart Touch” radiofrequency (Rosso
et al., 2016) and pulmonary vein ablation catheterisation (Laish-
Farkash et al., 2016) which uses two circular multi-electrode
catheters. Two studies divided the nMARQ sample into either
different technical approaches (Dello Russo et al., 2015) or into
the efficacy of nMARQ in paroxysmal and persistent AF (Vurma
et al., 2016). The baseline characteristics of these studies are
listed in Table 1. Three were retrospective studies and nine
were prospective studies. The mean follow-up duration was 9.3
months based on 11 out of 12 studies as one study did not provide
information regarding this.
Efficacy of the nMARQ Ablation Technique
Compared to Conventional Ablation
Techniques
The conventional ablation techniques include (i) “point-by-
point” radiofrequency using a single irrigated tip ablation
catheter and (ii) pulmonary vein ablation catheter, which uses
two circular multi-electrode catheters. Three studies compared
nMARQ with single-tip ablation catheter and one with the two
circular multi-electrode catheters. A total of 158 patients were
treated with nMARQ compared to 196 patients undergoing
conventional ablation procedures (Table 2). The mean age for
the conventional ablation group was 61.5± 10.5 years and 61.2%
of the subjects were male. The mean total procedure time was
103.8 ± 32.4min and the mean total fluoroscopy time was 27.9
± 12.4min. Our meta-analysis shows that the recurrence rate
of AF using nMARQ was not significantly different from that
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of traditional ablation procedures (OR = 0.97, 95% confidence
interval: 0.59–1.61; Figure 2).
Peri-Procedural Complications
All studies included in the analysis provided data on
perioperative complications. A total of 47 peri-procedural
complications (4.19%) occurred in the nMARQ group (n =
1123) while complications were observed in 6 patients (3.06%)
in the conventional ablation group (n = 196). The following
complications occurred following the use of nMARQ: groin
hematomas (n = 17), transient ST-segment elevation (n = 8),
access site injury (n = 8), death (n = 4), pericardial tamponade
(n= 4), pericardial effusion (n= 3), phrenic nerve palsy (n= 1),
oesophageal lesion (n = 1), charring injury (n = 1). Regarding
the complications with the conventional ablation techniques
the following occurred: transient ST-segment elevation (n =
3), access site injuries (n = 2), groin haematoma (n = 1). In
terms of peri-procedural mortality, four were reported in the
nMARQ group from the Mahida et al. and Vurma et al. studies
(Mahida et al., 2015; Vurma et al., 2016). Three deaths were
attributed to procedure-induced esophageal-pericardial fistulae.
The remaining death was due to sepsis (Mahida et al., 2015). By
contrast, there was zero mortality in the conventional ablation
group.
Additionally, when head-to-head analysis was conducted, the
conventional ablation group was associated with lower odds of
periprocedural complications (Odds ratio: 2.59; 95% CI: 0.98–
6.80; P = 0.05). In the head-to-head analysis, the nMARQ
group had 1 phrenic nerve palsy, 1 oesophageal lesion, 1
groin haematoma, 1 charring injury, 1 pericardial tamponade, 1
pericardial effusion, 3 transient ST-elevations and 4 access site
injuries. In the conventional ablation group there was only 1
haematoma, 3 transient ST-elevations, and 2 access site injuries.
DISCUSSION
This systematic review andmeta-analysis evaluated the efficacy of
the nMARQ catheter against conventional ablation approaches.
Since the main objective of ablation is to treat drug-resistant AF,
this study defined AF recurrence as the end-point. All studies
adhered to the post-ablation follow-up 2016 ESC guidelines for
the management of AF developed in collaboration with EACTS.
Physical examinations, evaluation of symptoms, 12-lead ECG
recordings, transthoracic echocardiography and Holter ECG
recordings (ranging between 1 and 7 days) were included in
follow-up monitoring. According to multiple studies included
in this meta-analysis AF recurrence is assumed as any atrial
tachyarrhythmia lasting at least 30 s on an ECG loop recorder or
ECG, regardless if it is organized into flutter or not.
The main findings are that (i) the use of the nMARQ
catheter is a useful technique in resolving treatment resistant AF
accompanied by low rates of recurrences; ii) when cross-analyzed
with conventional techniques, nMARQ is equally as effective
as conventional ablation procedures; iii) overall periprocedural
complication risk was greater with the use of nMARQ compared
to conventional techniques, iv) when mortality was analyzed as a
separate end-point higher mortality was observed in the nMARQ
group but this did not achieve statistical significance.
Procedural Parameters
The mean total procedure time (94.6 ± 18.7 vs. 103.8 ±
32.4) and fluoroscopy time (22.1 ± 8.8 vs. 27.9 ± 12.4) were
significantly shorter for nMARQ compared to conventional
approaches. This difference is due to the variability in the
transseptal and procedural approach. Some studies used a dual
trans-septal access approach while others used a single-access
approach without using a circular mapping catheter (CMC) to
confirm pulmonary vein isolation. Studies that used PVmapping
were found to have a longer fluoroscopy time of 31–35min
compared to the 20–24min fluoroscopy time in studies without
PV mapping (Wakili et al., 2016). Another possible difference
in the procedure and fluoroscopy time is the “learning curve.”
In Wakili et al. there was no observable trend in procedural
parameters with time. However, in Rosso et al. a significant
learning curve was observed with decreasing fluoroscopy and
procedural times (Wakili et al., 2016). Burning time was shorter
for nMARQ compared to PVAC. The longer total burning time
was attributed to the availability of 3D mapping used with
nMARQ and not with PVAC. Additionally, nMARQ ablation can
be stopped at any point after PV signals are no longer detected
after 1min (Wakili et al., 2016). In terms of left ventricular
ejection fraction (LVEF), the values were similar between the
nMARQ group (60.4 ± 10.3) and the “Usual” group, which were
only reported specifically by Wakili et al. and Lauschke et al. as
63.4± 7.1 and 59± 8 respectively.
Advantages of nMARQ Over Conventional
Ablation Techniques
The availability of 3D mapping with nMARQ confers many
advantages over conventional ablation techniques. It allows
visualization of catheter position in relation to the PV ostia,
guides voltage mapping of the atrium and adds location points
of the phrenic nerve route. Moreover, fluoroscopy time can be
reduced by using CARTO-MERGE technology. Lines of ablations
outside PV ostium can also be added. According to the same
study higher atrial arrhythmia incidence was observed for PVAC
when compared to nMARQ patients (95 vs. 36.5%, P = 0.0001).
The origin of the arrhythmogenic activity with PVAC system can
be due to the presence of a guide wire stimulating the PV ostia
or the different energy used with unipolar electrodes in nMARQ
compared to bipolar electrodes in PVAC (Wakili et al., 2016).
Concerns With Success in Achieving
Pulmonary Vein Isolation and
Peri-Procedural Complications in nMARQ
vs. Conventional Ablation Procedures
Confirming ablation success is impeditive for accurately
predicting AF recurrence. This is because an incomplete PVI will
more likely give rise to a post-procedural AF. The use of the
novel circulation ablation catheter, nMARQ, has raised concerns
with regard to its ability to successfully achieve successful PVI
(von Bary et al., 2011; Wakili et al., 2016). However, Scaglione
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FIGURE 2 | Efficacy of the nMARQ ablation technique compared to conventional ablation techniques.
et al. and Rosso et al. have adequately addressed this issue (Rosso
et al., 2014; Scaglione et al., 2014). Rosso et al. suggested that
the nMARQ catheter is associated with poor signal concordance
after radiofrequency (RF) application. Their group used a dual
transseptal approach instead of the single approach from the
start of the procedure, thereby potentially facilitating a successful
ablation of residual PV conduction by simultaneous PVmapping
with the CMC. The nMARQ most commonly missed persistent
atrial PV conduction which was observed in 30% of the examined
PVs using a CMC. Similarly, in Scaglione et al., 22% of PVs
were found to be persisting post-procedure even though the
nMARQ catheter suggested complete PVI. These findings are in
keeping with the many studies on nMARQ alone that have all
indicated >98% of PVIs are successful (Scaglione et al., 2014;
Zellerhoff et al., 2014; Mahida et al., 2015; Burri et al., 2016;
Rodriguez-Entem et al., 2016). This is an important aspect to
address as it will determine if nMARQ could effectively substitute
existing approaches or if supplementary post-RF conduction
is required to confirm ablation success (Wakili et al., 2016).
Indeed, Lauschke et al. confirmed that complete PV re-isolation
is possible with nMARQ (Lauschke et al., 2016). The difficulty
in sufficiently isolating the left-inferior pulmonary vein (LIPV)
was shown by Wakili et al. as greater RF energy is required
but it is also associated with oesophageal injury (Wakili et al.,
2016). Another possible complication includes phrenic nerve
palsy, which was reported in only one case and occurred
despite prophylactic phrenic nerve stimulation (Arroja and
Zimmermann, 2015).
In terms of oesophageal complications following ablation,
Halbfass et al. recently conducted a retrospective study into their
incidences in nMARQ vs. conventional ablation. A total 150
endoscopically detected oesophageal lesions were detected. Of
these 26 occurred in 149 patients undergoing nMARQ (17.4%)
and 124 occurred in 683 patients undergoing ablation using
single-tip catheters (18.2%). Of the 150 endoscopically detected
oesophageal lesions detected 98 were erosion injuries and 52 were
ulcers of which 5 (9.6%) progressed to perforation (Halbfass et al.,
2017).
Periprocedural Mortality in nMARQ vs.
Conventional Ablation Techniques
The published studies on nMARQ have demonstrated non-
statistically significant higher mortality rates when compared to
conventional ablation techniques (Mahida et al., 2015; Vurma
et al., 2016). Of the four deaths that occurred in the nMARQ
group, three were due to atrio-oesophageal fistulation and the
one due to sepsis. The only multi-center study was halted
immediately after the two fatalities were observed (Vurma et al.,
2016). Since then it has been recognized that lower power
settings were associated with less oesophageal damage (Dekker,
2016). It is possible that deaths could be prevented with lower
power settings and greater operator experience. The overall
mortality in the nMARQ group was 4.4% compared to 0% in the
conventional group. This may be due to different sample sizes
in the respective groups (1121 vs. 196). However, a multi-center
survey showed that mortality was 0.1% in a sample size of 32,569
patients. This incidence remains much lower than that reported
in our meta-analytical study for the nMARQ group (Cappato
et al., 2009). Further studies on the efficacy of nMARQ have
been stopped due to concerns of increased mortality with its
use.
LIMITATIONS
Several limitations of this study should be noted. Firstly,
a high degree of heterogeneity was found in our meta-
analysis, which may suggest that inconsistency of evidence
and therefore our results must be interpreted with caution.
This high degree of heterogeneity may be due to differences
in the baseline population characteristics between the groups,
such as age. Other potential contributing factors include the
difference in the proportion of patients with paroxysmal and
persistent AF and procedural times in each study. Secondly,
cumulative analysis for parameters such as mean LVEF was
not calculated due to the lack of information provided by
the respective studies. There is also no data with regard to
the inflammatory pathways and epigenetic modifications that
were reported in the included studies and these can have an
influence on therapeutic ablation response (Sardu et al., 2015,
2017).
CONCLUSION
AF recurrence rates are comparable between nMARQ
and conventional ablation techniques. Although general
complication rates are similar for both groups, the higher
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mortality with nMARQ suggests that conventional techniques
should be used for resistant AF until improved safety profiles of
nMARQ can be demonstrated.
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